Validity of self-reported cancer history: A comparison of health interview data and cancer registry records
Validity of self-reported cancer history: A comparison of health interview data and cancer registry records
复制标题
DOI：
10.1093/aje/153.3.299
复制
发表时间：
2001-02-01
影响因子：
5
通讯作者：
Druss, BG
中科院分区：
文献类型：
--
作者：
Desai, MM;Bruce, ML;Druss, BG
很少有研究涉及自我报告的癌症病史的准确性，尽管流行病学研究经常使用自我报告的信息作为暴露或结果数据的唯一来源，或作为排除参与研究的标准。在这篇文章中，通过将访谈数据与肿瘤登记记录进行比较，对社区样本中癌症病史的假阴性报告进行了检验，受试者是1980年纽黑文流行病学集水区研究的参与者；1995年，通过将样本链接到康涅狄格州肿瘤登记中心获得了癌症记录(自1935年起)。分析集中在263名在参加流行病学集水区研究之前向康涅狄格州肿瘤登记中心报告的至少有一个肿瘤的个人。总体漏检率为39.2%。Logistic回归分析显示，假阴性报告与非白衣架、高龄、癌症确诊后时间延长、既往肿瘤数量和接受的癌症治疗类型显著相关。此外，不同癌症部位的假阴性报告差异很大，从黑色素瘤皮肤癌的0%到中枢神经系统癌症的83.3%不等。乳腺癌假阴性率20.8%，结肠癌、前列腺癌假阴性率42.1%，膀胱癌假阴性率61.5%。讨论了这些发现对流行率估计和未来流行病学研究的影响。
Few studies have addressed the accuracy of self-reported cancer history, although epidemiologic studies routinely use self-reported information as the sole source of exposure or outcome data or as a criterion for exclusion from study participation. In this paper, false-negative reporting of cancer history is examined in a community-based sample by comparing interview data with tumor registry records, subjects were participants in the 1980 New Haven Epidemiologic Catchment Area study; in 1995, cancer records (from 1935 onward) were obtained by linking the sample to the Connecticut Tumor Registry. Analyses focused on 263 individuals who had at least one tumor reported to the Connecticut Tumor Registry prior to participation in the Epidemiologic Catchment Area study. The overall rate of false-negative reporting was 39.2%. Logistic regression analysis revealed that false-negative reporting was significantly associated with non-White rack, older age, increased time since cancer diagnosis, number of previous tumors, and type of cancer treatment received. In addition, false-negative reporting varied widely by cancer site, ranging from 0% for melanoma skin cancer to 83.3% for central nervous system cancers. The false-negative rate for breast cancer was 20.8%, that for colon and prostate cancers was 42.1%, and that for bladder cancer was 61.5%. Implications of these findings for prevalence estimation and future epidemiologic studies are discussed.